3 Horrendous Health-Care Stocks This Week

Why Amarin, Agios Pharmaceuticals, and Organovo were horrendous this week.

Jan 25, 2014 at 9:00AM

While the overall hot streak for health care continues unabated despite the latest signs of a pullback in the broader market, not every health-care stock is prospering. Here are three of this week's most horrendous performers.

Another "no"
Amarin
(NASDAQ:AMRN) just can't seem to catch a lucky break these days. Its shares sank nearly 25% this week on another negative decision by the U.S. Food and Drug Administration affecting the company's fish-oil drug Vascepa.

The company announced on Tuesday that the FDA denied Amarin's appeal of the agency's rescission of a Special Protocol Assessment for Vascepa. Amarin held a sliver of hope that the earlier decision would be overturned and clear the way for Vascepa to be marketed to the large group of Americans with high, but not extremely high, triglyceride levels. That friendly folks at the FDA dashed that hope.

Is Amarin now destined to move forward with a lengthy outcomes study? Probably -- but the company isn't giving up on changing the FDA's mind just yet. Amarin plans to appeal the latest decision. There's also the possibility fellow Fool Brian Orelli put forward recently that the FDA could allow Amarin to include results from its clinical study of moderate triglyceride levels in the packaging without receiving official approval for the expanded indication. 

Fading glow
At one point last week, shares of Agios Pharmaceuticals (NASDAQ:AGIO) were up 83% for the year. The stock is still up considerably year to date, but not nearly as much after dropping 21% this week.

Investors' excitement kicked into high gear as Agios presented at the J.P. Morgan Healthcare Conference on Jan. 13. Agios is working on several cancer drugs, most notably AG-221, which inhibits mutated IDH2 proteins. The stock pullback doesn't appear to be related to any concerns about the potential for Agios' pipeline, though. Part of the decline could just be that the glow from the J.P. Morgan conference is fading a bit.

There was another bit of news for Agios this week. Company Senior Vice President Glen Goddard sold 10,000 shares for a little over $347,000. That's a relatively insignificant amount in the big scheme of things, but some traders head for the exits when they see insiders selling. 

Short and not-so-sweet
One of the high flyers of the second half of 2013 lost some altitude this week, as 3-D bioprinting company Organovo Holdings (NYSEMKT:ONVO) slipped 18% following the posting of an "urgent trading warning to the public" by short-seller Citron Research.

Citron's warning focused primarily on alleged improper "cold calling" by Japanese firm Kanagawa Associates to encourage Swedish investors to buy Organovo stock. Citron also expressed concern about Organovo's high valuation with low institutional ownership and sparse analyst coverage.

It should be noted that Citron Research didn't direct its allegations against Organovo itself. And despite several accurate predictions of doom and gloom for stocks along the way (helped by Citron's own announcements), the short-seller's track record includes some misses. Last February, Citron attacked another 3-D printing company, 3D Systems (NYSE: DDD), calling it a "bubble stock." Since then, that so-called bubble stock has soared more than 80%. 

An investor's view
If you're a trader, letting go of a stock because of an adverse FDA decision, insider selling, or a short-seller attack makes sense. If you're an investor, though, a quick reaction isn't always the best move. For investors, all three of these stocks could have potential over the long run.

It might take a few years, but Amarin should still have a reasonable chance of gaining approval for Vascepa in treating more moderately high triglyceride levels. Agios' cancer drugs could prove to be big winners in the not-too-distant future. And Organovo's bioprinting technology could eventually revolutionize medicine.

Of course, all three companies could also stumble along the way. However, the horrendous stocks of today could become the humongous stocks of tomorrow.

One great investing idea for the here and now
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends and owns shares of 3D Systems. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers